Endocrine Business Growth
The endocrine business grew 20% on NRxs and 14% on TRxs, indicating strong performance and demand.
Strong Partnership with United Therapeutics
The collaboration with United Therapeutics resulted in Q1 royalty revenue of $30 million and manufacturing revenue of $29 million.
Non-GAAP Income Growth
Reported non-GAAP income of $22 million, showing a 43% growth over the previous year.
Afrezza Demand and Expansion
Successful interactions and increased demand at the ATTD conference, with a focus on global expansion and pediatric opportunities.
Tyvaso DPI Revenue and Market Potential
Received $29 million in manufacturing revenue from Tyvaso DPI, with the market expected to exceed $1 billion by the end of the decade.